开云app官网登录入口网页版-官方正版

#I期临床#

570篇内容 | 5075人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1653248, encodeId=e39c165324893, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=一线治疗晚期肝癌哪家强？《柳叶刀肿瘤学》发布卡博替尼+阿替利珠单抗 vs 索拉非尼III期临床结果, objectType=article, longId=731375, objectId=9d30e31375a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d30e31375a9, replyNumber=0, likeNumber=127, createdTime=2023-04-08, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d30e31375a9, moduleTitle=一线治疗晚期肝癌哪家强？《柳叶刀肿瘤学》发布卡博替尼+阿替利珠单抗 vs 索拉非尼III期临床结果, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=9d30e31375a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653246, encodeId=51151653246ed, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=J Clin Oncol：选择性雌激素受体降解剂（Elacestrant）对比标准内分泌治疗ER+/HR-晚期乳腺癌的疗效：III期临床研究EMERALD, objectType=article, longId=727795, objectId=19a7e27795a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19a7e27795a3, replyNumber=0, likeNumber=94, createdTime=2023-04-15, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19a7e27795a3, moduleTitle=J Clin Oncol：选择性雌激素受体降解剂（Elacestrant）对比标准内分泌治疗ER+/HR-晚期乳腺癌的疗效：III期临床研究EMERALD, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=19a7e27795a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653245, encodeId=a2f616532452d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=绿谷制药GV-971治疗阿尔茨海默病国际多中心III期临床停止, objectType=article, longId=726700, objectId=96ace26700f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96ace26700f7, replyNumber=0, likeNumber=88, createdTime=2023-03-15, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96ace26700f7, moduleTitle=绿谷制药GV-971治疗阿尔茨海默病国际多中心III期临床停止, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=96ace26700f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653249, encodeId=7e3b16532492e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Mazdutide (IBI362) 在中国超重或肥胖2型糖尿病II期临床研究达到主要终点, objectType=article, longId=732770, objectId=2432e3277073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2432e3277073, replyNumber=0, likeNumber=86, createdTime=2022-11-02, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2432e3277073, moduleTitle=Mazdutide (IBI362) 在中国超重或肥胖2型糖尿病II期临床研究达到主要终点, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=2432e3277073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653241, encodeId=bb0016532412b, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期, objectType=article, longId=301595, objectId=0e1630159509, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e1630159509, replyNumber=0, likeNumber=89, createdTime=2022-05-15, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e1630159509, moduleTitle=III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=0e1630159509)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653237, encodeId=55c9165323e61, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Front Oncol：III期临床研究XELAVIRI评估一线贝伐珠单抗为基础的续观治疗对比联合治疗转移性结直肠癌（mCRC）患者的疗效, objectType=article, longId=299336, objectId=5af529933624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5af529933624, replyNumber=0, likeNumber=83, createdTime=2022-05-12, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5af529933624, moduleTitle=Front Oncol：III期临床研究XELAVIRI评估一线贝伐珠单抗为基础的续观治疗对比联合治疗转移性结直肠癌（mCRC）患者的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=5af529933624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653233, encodeId=5f8c16532331d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Clin Cancer Res: Olaparib(奥拉帕利)单药维持治疗亚洲人群铂敏感复发卵巢癌的疗效：III期临床研究L-MOCA, objectType=article, longId=295346, objectId=6f04295346b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f04295346b6, replyNumber=0, likeNumber=99, createdTime=2022-07-02, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f04295346b6, moduleTitle=Clin Cancer Res: Olaparib(奥拉帕利)单药维持治疗亚洲人群铂敏感复发卵巢癌的疗效：III期临床研究L-MOCA, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=6f04295346b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653238, encodeId=adbf1653238bd, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Clin Cancer Res：III期临床研究CATNON表明IDH野生型的胶质母细胞瘤中，在放疗的基础上加用替莫唑胺并不能改善患者的预后, objectType=article, longId=300739, objectId=32fb300e39e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32fb300e39e8, replyNumber=0, likeNumber=91, createdTime=2022-04-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32fb300e39e8, moduleTitle=Clin Cancer Res：III期临床研究CATNON表明IDH野生型的胶质母细胞瘤中，在放疗的基础上加用替莫唑胺并不能改善患者的预后, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=32fb300e39e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653229, encodeId=dd3f16532294d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Chin J Cancer Res：阿帕替尼单药或联合治疗HER2阴性乳腺癌伴有胸壁转移患者的疗效：多中心II期临床研究, objectType=article, longId=292393, objectId=a3232923933c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3232923933c, replyNumber=0, likeNumber=92, createdTime=2022-01-14, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3232923933c, moduleTitle=Chin J Cancer Res：阿帕替尼单药或联合治疗HER2阴性乳腺癌伴有胸壁转移患者的疗效：多中心II期临床研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a3232923933c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653240, encodeId=1c22165324028, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究, objectType=article, longId=302280, objectId=14b430228084, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14b430228084, replyNumber=0, likeNumber=88, createdTime=2022-11-17, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14b430228084, moduleTitle=Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=14b430228084)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653224, encodeId=849a16532246e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Oncologist: Anlotinib（安罗替尼）联合S-1三线或后线治疗晚期NSCLC患者的疗效和安全性：II期临床研究, objectType=article, longId=221301, objectId=e3df221301c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3df221301c8, replyNumber=0, likeNumber=102, createdTime=2022-08-19, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3df221301c8, moduleTitle=Oncologist: Anlotinib（安罗替尼）联合S-1三线或后线治疗晚期NSCLC患者的疗效和安全性：II期临床研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e3df221301c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653222, encodeId=d377165322288, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Nat Commun：胃切除术联合术中广泛腹腔灌洗(EIPL)治疗局部进展期胃癌(AGC)患者的3年生存分析： III期临床研究SEIPLUS, objectType=article, longId=220829, objectId=c5ee220829b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5ee220829b8, replyNumber=0, likeNumber=97, createdTime=2022-09-17, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5ee220829b8, moduleTitle=Nat Commun：胃切除术联合术中广泛腹腔灌洗(EIPL)治疗局部进展期胃癌(AGC)患者的3年生存分析： III期临床研究SEIPLUS, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c5ee220829b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653239, encodeId=1ddf16532397d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=君实生物口服抗新冠病毒药物VV116公布3项I期临床数据, objectType=article, longId=301010, objectId=cbcc301010a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbcc301010a0, replyNumber=0, likeNumber=95, createdTime=2022-07-20, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbcc301010a0, moduleTitle=君实生物口服抗新冠病毒药物VV116公布3项I期临床数据, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=cbcc301010a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653225, encodeId=dfac16532259e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Oncologist:化疗难治性食管鳞状细胞癌患者使用apatinib（阿帕替尼）的疗效和安全性：II期临床研究, objectType=article, longId=221311, objectId=7491221311ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7491221311ab, replyNumber=0, likeNumber=82, createdTime=2022-06-08, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7491221311ab, moduleTitle=Oncologist:化疗难治性食管鳞状细胞癌患者使用apatinib（阿帕替尼）的疗效和安全性：II期临床研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=7491221311ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653219, encodeId=7cdc1653219bc, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=乐复能治疗重症新冠肺炎III期临床试验数据公布，降低重症病人的呼吸衰竭和死亡率58.3%, objectType=article, longId=219794, objectId=be3b219e94bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be3b219e94bc, replyNumber=0, likeNumber=104, createdTime=2022-04-30, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be3b219e94bc, moduleTitle=乐复能治疗重症新冠肺炎III期临床试验数据公布，降低重症病人的呼吸衰竭和死亡率58.3%, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=be3b219e94bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653198, encodeId=dbaa1653198e7, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=科济药业发布2021年中期业绩自主研发 CAR-T候选品进入海外关键II期临床试验, objectType=article, longId=216260, objectId=c3532162608a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3532162608a, replyNumber=0, likeNumber=88, createdTime=2021-10-07, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3532162608a, moduleTitle=科济药业发布2021年中期业绩自主研发 CAR-T候选品进入海外关键II期临床试验, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c3532162608a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653215, encodeId=04a7165321510, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果, objectType=article, longId=218769, objectId=9c2d218e69ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c2d218e69ce, replyNumber=0, likeNumber=87, createdTime=2022-04-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c2d218e69ce, moduleTitle=J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=9c2d218e69ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653231, encodeId=526b165323178, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, objectType=article, longId=294057, objectId=20b829405e40, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20b829405e40, replyNumber=0, likeNumber=73, createdTime=2022-04-28, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20b829405e40, moduleTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=20b829405e40)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653206, encodeId=1d4a1653206dc, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=布美他尼用于自闭症III期临床试验失败, objectType=article, longId=217084, objectId=f94e21e084df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f94e21e084df, replyNumber=0, likeNumber=96, createdTime=2022-04-01, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f94e21e084df, moduleTitle=布美他尼用于自闭症III期临床试验失败, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f94e21e084df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653196, encodeId=3bf01653196cf, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=我国人造红细胞研究标志性成果 ——“人造万用血”即将进入Ⅰ期临床研究阶段, objectType=article, longId=214483, objectId=58502144839a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58502144839a, replyNumber=0, likeNumber=98, createdTime=2021-12-09, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58502144839a, moduleTitle=我国人造红细胞研究标志性成果 ——“人造万用血”即将进入Ⅰ期临床研究阶段, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=58502144839a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

一线治疗晚期肝癌哪家强？《柳叶刀肿瘤学》发布卡博替尼+阿替利珠单抗 vs 索拉非尼III期临床结果

2023-04-08

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

J Clin Oncol：选择性雌激素受体降解剂（Elacestrant）对比标准内分泌治疗ER+/HR-晚期乳腺癌的疗效：III期临床研究EMERALD

2023-04-15

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

绿谷制药GV-971治疗阿尔茨海默病国际多中心III期临床停止

2023-03-15

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Mazdutide (IBI362) 在中国超重或肥胖2型糖尿病II期临床研究达到主要终点

2022-11-02

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期

2022-05-15

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Front Oncol：III期临床研究XELAVIRI评估一线贝伐珠单抗为基础的续观治疗对比联合治疗转移性结直肠癌（mCRC）患者的疗效

2022-05-12

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Clin Cancer Res: Olaparib(奥拉帕利)单药维持治疗亚洲人群铂敏感复发卵巢癌的疗效：III期临床研究L-MOCA

2022-07-02

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Clin Cancer Res：III期临床研究CATNON表明IDH野生型的胶质母细胞瘤中，在放疗的基础上加用替莫唑胺并不能改善患者的预后

2022-04-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Chin J Cancer Res：阿帕替尼单药或联合治疗HER2阴性乳腺癌伴有胸壁转移患者的疗效：多中心II期临床研究

2022-01-14

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究

2022-11-17

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Oncologist: Anlotinib（安罗替尼）联合S-1三线或后线治疗晚期NSCLC患者的疗效和安全性：II期临床研究

2022-08-19

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Nat Commun：胃切除术联合术中广泛腹腔灌洗(EIPL)治疗局部进展期胃癌(AGC)患者的3年生存分析： III期临床研究SEIPLUS

2022-09-17

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

君实生物口服抗新冠病毒药物VV116公布3项I期临床数据

2022-07-20

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Oncologist:化疗难治性食管鳞状细胞癌患者使用apatinib（阿帕替尼）的疗效和安全性：II期临床研究

2022-06-08

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

乐复能治疗重症新冠肺炎III期临床试验数据公布，降低重症病人的呼吸衰竭和死亡率58.3%

2022-04-30

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

科济药业发布2021年中期业绩自主研发 CAR-T候选品进入海外关键II期临床试验

2021-10-07

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果

2022-04-06

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效

2022-04-28

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

布美他尼用于自闭症III期临床试验失败

2022-04-01

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

我国人造红细胞研究标志性成果 ——“人造万用血”即将进入Ⅰ期临床研究阶段

2021-12-09

科室
- - 订阅+
  - 更多科室
工具
服务